The role of anti-inflammatory diets and supplementation in metabolic syndrome and symptom remission in adults with schizophrenia: a systematic review
Open Access
- 7 January 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1506353
Abstract
Introduction: Immune dysregulation and chronic inflammation have been hypothesized as potential pathways in metabolic syndrome and schizophrenia. Anti-inflammatory diets have the potential not only to treat metabolic syndrome but also to reduce the symptom burden in schizophrenia. The aim of this systematic review was to investigate the role of anti-inflammatory diets and vitamin supplementation in the management of metabolic syndrome and in symptom remission in people with schizophrenia.Methods: This systematic review included research articles from PubMed, EMBASE, Scopus, PsycINFO, and the Cochrane Central Register for Controlled Trials. The primary outcomes were markers of metabolic syndrome and symptoms of psychosis.Results: Our search identified 2,124 potential studies, of which 1,559 were screened based on the title and abstract, resulting in 81 full-text articles assessed for eligibility. A total of 17 studies were included, which demonstrated mixed findings on the impacts of anti-inflammatory diet interventions on metabolic markers and symptom remission in schizophrenia. Prebiotic, probiotic, and fish oil supplementation showed improvements in metabolic markers. Fish oil and vitamin D supplementation demonstrated symptom remission in some trials.Conclusion: It is important to consider that people with schizophrenia may experience common external barriers that hinder adherence to dietary interventions. These findings underscore the need for larger trials with standardized dietary protocols and consistent metabolic and symptom outcome measures in order to better understand the potential role of anti-inflammatory interventions in this population.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024511596.Keywords
This publication has 49 references indexed in Scilit:
- Global Prevalence of Metabolic Syndrome in Schizophrenia Patients: A Systematic Review and Meta-AnalysisJournal of Prevention, 2024
- Potential Roles of Redox Dysregulation in the Development of SchizophreniaBiological Psychiatry, 2020
- Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidenceJournal of Neural Transmission, 2015
- Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approachPsychoneuroendocrinology, 2014
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- Randomized Multicenter Investigation of Folate Plus Vitamin B12Supplementation in SchizophreniaJAMA Psychiatry, 2013
- Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophreniaMetabolic Brain Disease, 2009
- MicrogliaCurrent Biology, 2008
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Is Schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisitedJournal of Psychiatric Research, 1994